Stifel Resumes Mirum Pharmaceuticals (MIRM) at Buy, PT $89, 'stands out in what remains a discerning biotech tape'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mirum Pharmaceuticals (MIRM) PT Raised to $85 at Cantor Fitzgerald
August 7, 2025 9:30 AM EDTCantor Fitzgerald analyst Josh Schimmer raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $85.00 (from $75.00) while maintaining a Overweight rating.... More
Mirum Pharmaceuticals (MIRM) PT Raised to $75 at Morgan Stanley
August 7, 2025 8:22 AM EDTMorgan Stanley analyst Michael E Ulz raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $75.00 (from $70.00) while maintaining a Overweight rating.... More
Mirum Pharmaceuticals (MIRM) PT Raised to $72 at Baird
August 7, 2025 7:51 AM EDTBaird analyst Brian Skorney raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $72.00 (from $55.00) while maintaining a Outperform rating.... More
Mirum Pharmaceuticals (MIRM) PT Raised to $80 at H.C. Wainwright
August 7, 2025 6:50 AM EDT(Updated - August 7, 2025 7:18 AM EDT)
H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $80.00 (from $73.00) while maintaining a Buy rating.
The analyst commented: "Mirum Pharmaceuticals reported 2Q25 total revenues of $127.8M, up... More
Mirum Pharmaceuticals (MIRM) PT Raised to $81 at Citizens JMP
August 7, 2025 4:17 AM EDTCitizens JMP analyst Jonathan Wolleben raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $81.00 (from $79.00) while maintaining a Market Outperform rating.
The analyst commented, "Livmarli and bile acid sales continue to exceed expectations and management once again raised its 2025 guidance to $490M-$510M, representing 48% Y/Y growth at the midpoint. Management highlighted that strong 2Q U.S. Livmarli sales of $57M were... More
